ReviewAntibiotics (Basel, Switzerland)2021
Antibiotics and Liver Cirrhosis: What the Physicians Need to Know.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.The Journal of antimicrobial chemotherapy · 2024Pooled it
- Article
- Albumin-on-a-chip: binding profiling of circulating human albumin via selective immunocapture and real-time SPR analysis.Scientific reports · 2026Article
- Early piperacillin exposure during continuous infusion in critically ill patients: the impact of renal and liver dysfunctions.Annals of intensive care · 2026Article
- Dual Impact of Iron Deficiency and Antibiotics on Host Metabolism: A Tissue-Level Analysis.Metabolites · 2025Article
- Importance of hospital-specific antibiotic policy for ensuring maternal quality of care in India: A narrative review.Journal of family medicine and primary care · 2025Review
- Impact of Quinolone Prophylaxis on Spontaneous Bacterial Peritonitis and Mortality in Cirrhosis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Evaluating the Clinical Endpoint of Antibiotic Prophylaxis for Cirrhosis Patients Complicated with Upper Gastrointestinal Bleeding: An Updated Systematic Review and Meta-analysis.Acta medica Philippina · 2025Article
- Serum direct bilirubin predicts severe tricuspid regurgitation in atrial fibrillation.Frontiers in cardiovascular medicine · 2025Article
- Spontaneous Bacterial Peritonitis: Etiology, Microbiology, and Clinical Outcomes in Cirrhosis Patients.Cureus · 2024Article
- Article
- Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle.World journal of clinical cases · 2023Review
- Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Safety and Tolerability of Antimicrobial Agents in the Older Patient.Drugs & aging · 2023Review
- Emerging concepts in the care of patients with cirrhosis and septic shock.World journal of hepatology · 2023Review
- Clinical Characteristics and Early Diagnosis of Spontaneous Fungal Peritonitis/Fungiascites in Hospitalized Cirrhotic Patients with Ascites: A Case-Control Study.Journal of clinical medicine · 2023Article
- Protective role of resveratrol against VCM-induced hepatotoxicity in male wistar rats.Frontiers in pharmacology · 2023Article
- Trust Your Gut: The Association of Gut Microbiota and Liver Disease.Microorganisms · 2022Review
- Editorial for the Special Issue: "Antibiotic Use in Clinical Infection: How to Reinvent Old Molecules and How to Squeeze out New Ones".Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver is the primary site of drug metabolism, which can be altered by a variety of diseases affecting the liver parenchyma, especially in patients with liver cirrhosis. The use of antibiotics in patients with cirrhosis is usually a matter of concern for physicians, given the lack of practical knowledge for drug choice and eventual dose adjustments in several clinical scenarios. The aim of the current narrative review is to report, as broadly as possible, basic, and practical knowledge that any physician should have when approaching a patient with liver cirrhosis and an ongoing infection to efficiently choose the best antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.